Costlier PDPs, Cheaper MA-PDs Opt Into Insulin Demonstration

In 2021, about half of enhanced stand-alone Prescription Drug Plans (PDPs) and a little more than a third of Medicare Advantage-Prescription Drug (MA-PD) plans will participate in a new demonstration that aims to lower diabetic seniors’ out-of-pocket costs by capping copays at $35 for a broad set of insulin products. That’s one finding from a new analysis by consulting firm Avalere Health, which also uncovered some illuminating trends regarding how plan sponsors chose to price PDPs and MA-PD plans featuring the new benefit.

Among the 310 enhanced PDPs that opted to participate in CMS’s Part D Senior Savings Model for 2021, the average enrollment-weighted premium is $57.53 — $23.46 higher than the average premium for non-participating plans, the analysis found. But an opposite scenario is playing out in the MA-PD space, where the average enrollment-weighted premium for the 1,287 participating plans is $10.36 less than the cost of non-participating plans ($22.74 versus $33.10).

© 2023 MMIT
Leslie Small

Leslie Small

Leslie has been reporting and editing in various journalism roles for nearly a decade. Most recently, she was the senior editor of FierceHealthPayer, an e-newsletter covering the health insurance industry. A graduate of Penn State University, she previously served in editing roles at newspapers in Pennsylvania, Virginia and Colorado.

Related Posts

businessman-viewing-news-update-journalism-headline-on-a-laptop
November 22

News Briefs: CDC Makes More RSV Immunizations Available to Infants

READ MORE
dna-strand
November 22

Papers Delve Into Payment Options for Gene Therapies

READ MORE
pills
November 22

A Closer Look at the Medicare Part D Landscape

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today